{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:22:12Z","timestamp":1780392132248,"version":"3.54.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Plasma cytokine levels were quantified among 30 persons with HIV (PWH) identified as elite controllers (15 transient controllers [studied a median of 1.38 years before losing viral control] and 15 persistent controllers). Thirty antiretroviral therapy (ART)-naive PWH, 30 ART-treated PWH with undetectable viremia, and 30 HIV-uninfected controls also were studied. Higher levels of cytokines were recognized among PWH than among controls, with EC displaying the highest levels. Elevated levels of IP-10 and MIG were identified among transient controllers as predictors of the loss of viral control. These findings offer feasible biomarkers for predicting virologic outcome and loss of control in EC.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1446730","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:01:10Z","timestamp":1724907670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Elevated plasma levels of IP-10 and MIG are early predictors of loss of control among elite HIV controllers"],"prefix":"10.3389","volume":"15","author":[{"given":"Eva","family":"Poveda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Alonso-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Aguayo-Arjona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortensia","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Valcarce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"B1","unstructured":"HIV and AIDS"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1086\/433188","article-title":"HIV controllers: A homogeneous group of HIV-1\u2013infected patients with spontaneous control of viral replication","volume":"41","author":"Lambotte","year":"2005","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy","volume":"27","author":"Deeks","year":"2007","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328344f35e","article-title":"Epidemiology and clinical characteristics of elite controllers","volume":"6","author":"Okulicz","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"B5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.20411\/pai.v5i1.364","article-title":"Antiretroviral treatment for HIV elite controllers","volume":"5","author":"Ruiz-Mateos","year":"2020","journal-title":"Pathog Immun"},{"key":"B6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.antiviral.2009.08.007","article-title":"Effector mechanisms in HIV-1 infected elite controllers: Highly active immune responses","volume":"85","author":"Blankson","year":"2010","journal-title":"Antiviral Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01805-17","article-title":"Factors leading to the loss of natural elite control of HIV-1 infection","volume":"92","author":"Pernas","year":"2018","journal-title":"J Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy599","article-title":"Proteomic profile associated with loss of spontaneous human immunodeficiency virus type 1 elite control","volume":"219","author":"Rodr\u00edguez-Gallego","year":"2019","journal-title":"J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257725","article-title":"IP-10 and MIG are sensitive markers of early virological response to HIV-1 integrase inhibitors","volume":"14","author":"\u00c1lvarez","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01144.x","article-title":"Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)\u2014possible immunosuppressive role of IFN-\u03b1 in HIV infection","volume":"119","author":"Stylianou","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2012.7","article-title":"A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers","volume":"5","author":"Lajoie","year":"2012","journal-title":"Mucosal Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad042","article-title":"Interleukin 18 (IL-18) and IL-3 in extracellular vesicles: biomarkers for durable elite control of HIV-1","volume":"227","author":"Poveda","year":"2023","journal-title":"J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01576","article-title":"Plasmatic levels of IL-18, IP-10, and activated CD8+ T cells are potential biomarkers to identify HIV-1 elite controllers with a true functional cure profile","volume":"9","author":"C\u00f4rtes","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.1.407","article-title":"IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction","volume":"178","author":"Miss\u00e9","year":"2007","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw275","article-title":"Immunologic biomarkers, morbidity, and mortality in treated HIV infection","volume":"214","author":"Hunt","year":"2016","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.05.008","article-title":"One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study","volume":"8","author":"Psomas","year":"2016","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1446730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:01:15Z","timestamp":1724907675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1446730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2024.1446730"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1446730","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"article-number":"1446730"}}